Daiichi Sankyo stock gets Citi Buy rating with JPY 4,700 target

Published on 10/08/2026 at 04:25 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

On October 7, 2026, Citi kept a Buy view on Daiichi Sankyo. June-quarter revenue reached JPY 574.74 billion, up from JPY 474.6 billion.

Daiichi Sankyo, JP3475350009, Illustration mit AI erstellt.

Daiichi Sankyo stock (ISIN JP3475350009) was last at JPY 2,718.00 on the Tokyo Stock Exchange on October 8, 2026, down 1.24 percent. On October 7, 2026, Citi maintained a Buy rating and set a JPY 4,700.00 price target, as reported by Markets Insider.

Citi sees room above JPY 4,700

The Citi target stands 72.9 percent above the Tokyo price of JPY 2,718.00. That comparison is the clearest market measure in the latest analyst update because the target and the reference price use the same currency and listed company.

The broader consensus is Moderate Buy with a consensus target of JPY 3,897.41, according to Markets Insider. That consensus target is 43.4 percent above the Tokyo price, leaving the analyst view materially higher than the latest traded level.

Revenue rises while profit falls

For the quarter ended June 30, 2026, Daiichi Sankyo reported revenue of JPY 574.74 billion, compared with JPY 474.6 billion in the year-earlier quarter. Net profit was JPY 68.64 billion, down from JPY 85.5 billion, according to Markets Insider.

The contrast matters for the valuation debate: revenue increased 21.1 percent year over year, while net profit declined 19.7 percent. Earlier quarterly reporting cited by market coverage attributed pressure to restructuring, quality adjustments, profit sharing and higher costs, keeping execution and margins central to the stock story.

October 30 results are next

Daiichi Sankyo's investor page lists the FY2026 second-quarter financial results briefing for October 30, 2026, giving investors a defined checkpoint for sales momentum, profitability and management guidance. The company develops and sells pharmaceutical products in Japan and international markets, with oncology medicines including Enhertu and Datroway forming a major part of its commercial profile.

Stock trades below its yearly high

The JPY 2,718.00 intraday price on October 8, 2026, stood within a 52-week range of JPY 2,390.00 to JPY 4,178.00. Market capitalization was JPY 4.946 trillion and trading volume was 1,665,400 shares at the quoted time of 11:30 a.m. JST.